Table 2

Plasma Levels of Fibrinolytic Parameters at Baseline, After VO, and x-Fold Increase

TotalLow Risk (CRP <1.0 mg/l)Medium Risk (CRP 1.0–2.9 mg/l)High Risk (CRP ≥3.0 mg/l)p Value
Before VO
 t-PA activity (IU/ml)0.30 (0.10–0.70)0.20 (0.10–0.58)0.20 (0.10–0.35)0.80 (0.35–1.50)0.005
 t-PA antigen (ng/ml)5.8 (3.7–7.1)5.8 (4.0–8.3)5.8 (4.0–8.3)6.8 (3.8–9.4)0.679
 PAI-1 activity (IU/ml)8.3 (2.9–16.3)5.3 (2.9–14.1)8.8 (2.8–22.9)11.7 (2.1–17.6)0.588
 PAI-1 antigen (ng/ml)108.1 (57.6–193.8)66.2 (44.8–107.8)160.1 (118.0–210.1)101.7 (58.0–206.9)0.012
 t-PA/PAI-1 complexes (ng/ml)26.9 (18.0–36.6)22.6 (15.5–30.9)28.9 (16.8–45.2)33.3 (19.4–44.0)0.203
 Ratio of t-PA/PAI-1 activity0.046 (0.012–0.12)0.044 (0.006–0.19)0.017 (0.006–0.091)0.085 (0.028–4.10)0.199
After VO
 t-PA activity (IU/ml)0.74 (0.26–2.14)1.35 (0.35–2.25)0.34 (0.18–0.79)1.34 (0.53–3.58)0.015
 t-PA antigen (ng/ml)11.9 (9.1–18.3)12.8 (8.1–19.7)12.4 (10.1–15.8)10.4 (8.8–16.5)0.564
 PAI-1 activity (IU/ml)3.5 (0.1–13.3)0.1 (0.1–5.6)8.3 (1.4–19.1)8.6 (0.1–16.6)0.054
 PAI-1 antigen (ng/ml)67.7 (33.8–156.1)41.5 (23.3–66.3)143.4 (103.5–214.3)66.5 (40.4–146.2)0.003
 t-PA/PAI-1 complexes (ng/ml)50.4 (30.1–76.4)36.4 (28.3–100.1)55.3 (28.2–84.8)52.4 (40.9–64.5)0.679
 Ratio of t-PA/PAI-1 activity0.27 (0.025–7.59)3.65 (0.29–22.02)0.054 (0.007–0.49)0.16 (0.029–2.62)0.051
x-fold change
 t-PA activity1.9 (1.4–3.6)2.7 (1.9–7.6)1.7 (1.2–3.0)1.7 (1.2–2.3)0.028
 t-PA antigen1.9 (1.5–3.0)2.5 (1.5–3.3)1.8 (0.8–2.9)1.7 (1.1–2.3)0.167
 PAI-1 activity0.62 (0.04–0.86)0.048 (0.019–0.72)0.69 (0.31–0.87)0.83 (0.59–0.90)0.028
 PAI-1 antigen0.83 (0.64–0.93)0.84 (0.60–0.92)0.88 (0.69–0.96)0.72 (0.61–0.87)0.331
 t-PA/PAI-1 complexes1.7 (1.3–2.6)2.0 (1.4–2.8)1.6 (1.1–3.1)1.6 (1.2–2.2)0.676

Values are median (interquartile range). Statistical differences were determined by the Kruskal-Wallis test.

CRP = C-reactive protein; PAI-1 = plasminogen activator inhibitor type-1; t-PA = tissue-type plasminogen activator; VO = venous occlusion.